176 related articles for article (PubMed ID: 32535892)
1. Optimality of testing procedures for survival data in the nonproportional hazards setting.
Arfè A; Alexander B; Trippa L
Biometrics; 2021 Jun; 77(2):587-598. PubMed ID: 32535892
[TBL] [Abstract][Full Text] [Related]
2. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
3. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
4. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
5. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
6. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
7. Improving testing and description of treatment effect in clinical trials with survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):530-544. PubMed ID: 29671899
[TBL] [Abstract][Full Text] [Related]
8. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
9. Window mean survival time.
Paukner M; Chappell R
Stat Med; 2021 Nov; 40(25):5521-5533. PubMed ID: 34258772
[TBL] [Abstract][Full Text] [Related]
10. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
11. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
12. Two-sample inference procedures under nonproportional hazards.
Tai YC; Wang W; Wells MT
Pharm Stat; 2023; 22(6):1016-1030. PubMed ID: 37429738
[TBL] [Abstract][Full Text] [Related]
13. Bayesian nonparametric nonproportional hazards survival modeling.
De Iorio M; Johnson WO; Müller P; Rosner GL
Biometrics; 2009 Sep; 65(3):762-71. PubMed ID: 19210742
[TBL] [Abstract][Full Text] [Related]
14. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
15. Bayesian randomized clinical trials: From fixed to adaptive design.
Yin G; Lam CK; Shi H
Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
[TBL] [Abstract][Full Text] [Related]
16. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
Kim HT; Gray R
Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
[TBL] [Abstract][Full Text] [Related]
17. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
18. Tests for equivalence of two survival functions: Alternative to the tests under proportional hazards.
Martinez EE; Sinha D; Wang W; Lipsitz SR; Chappell RJ
Stat Methods Med Res; 2017 Feb; 26(1):75-87. PubMed ID: 24925887
[TBL] [Abstract][Full Text] [Related]
19. Bayesian analysis of generalized odds-rate hazards models for survival data.
Banerjee T; Chen MH; Dey DK; Kim S
Lifetime Data Anal; 2007 Jun; 13(2):241-60. PubMed ID: 17401683
[TBL] [Abstract][Full Text] [Related]
20. Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
Demirhan H; Demirhan YP; Bacanli S
J Biopharm Stat; 2013 Mar; 23(2):447-60. PubMed ID: 23437950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
